HPV-RNA – detection of mRNA of E6 and E7 oncogenes – PCR method – genetic testing

• The test material is a smear from the cervix.

  The test should not be performed:
  – during menstruation,
  – during treatment with antibiotics or steroids,
  – during treatment with vaginal preparations (pessories, creams),
  – when using douches,
  – within 48 hours of the last sexual intercourse.
  If treatment was used, a 3-5-day break is recommended between the end of treatment
  and the test.
  Moisturizers, intimate hygiene products, and contraceptive gels
  (except Advantage – S ® Bioadhesive Contraceptive Gel) do not interfere with the test.

Samples brought in from outside the home are not accepted for testing.
We do not perform testing on men.
For men, choose a test that detects HPV DNA:
HPV-GENETIC TESTING (14 GENOTYPES) ​​or HPV-GENETIC TESTING (16 GENOTYPES), depending on the clinical condition. The HPV-16 genotype test is useful when genital warts are suspected.

The test detects mRNA transcripts of high-risk HPV genotypes (16, 18, 31, 33, and 45). This test is recommended by the Gynecological Society and the Central Coordinating Center for the Population-Based Prevention Program

and Early Detection of Cervical Cancer for patients who have received an abnormal Pap smear result.

The HPV mRNA test is much more sensitive than the basic HPV test, which we also offer, because it detects viral activity leading to the development of cancer, not the presence of the virus itself.

EXTENDED INFO

Testing for HPV infection (HPV mRNA) – HIGH ONCOGENIC RISK

enables the detection of active oncogenes E6 and E7 of the high-risk oncogenic HPV virus types 16, 18, 31, 33, 45. High-risk HPV viruses are considered to be the main factor in the development of cervical cancer (their presence is detected in 97-99.7% of cervical cancer cases).

The HPV oncogenes E6 and E7 are a significant factor in the development of changes in cervical cells that can lead to the development of cervical cancer. Their synthesis occurs primarily in cases of persistent high-risk HPV infections (in approximately 80% of HPV infections, the infection is fought by the woman's immune system). Therefore, a positive result obtained with the NucliSENS EasyQ HPV test more accurately indicates an increased likelihood of developing invasive cervical cancer than more commonly available HPV DNA tests.

The need for testing should be determined by a gynecologist.

It is recommended for women of all ages, including those who have previously been diagnosed with oncogenic HPV DNA.

These tests utilize advanced technologies using state-of-the-art reagents and equipment, CE-IUD certified for clinical use. Rigorous quality control systems must be adhered to.

ADDITIONAL INFORMATION:

Most women fight the virus before it causes adverse effects. Abnormal cells develop in the cervical epithelium only when an infection with oncogenic HPV types persists. In most cases, the body of a healthy, young woman (under 30 years of age) will destroy the virus. In such a situation, all signs of infection—including abnormal cervical cells—will disappear spontaneously after 6-24 months. However, sometimes an infection with oncogenic HPV types becomes persistent, in which the virus overproduces the so-called EB/E7 oncoprotein mRNA, which is directly responsible for initiating cancer processes in the cervix. This results in the development of precancerous changes in the cervical epithelium over time (usually several months to several years), known as dysplasia, CIN, or SIL. Untreated advanced dysplasia (so-called CIN III or HSIL) can lead to the development of the disease. Prevention, early detection, and treatment of dysplasia caused by oncogenic HPV viruses protect most women from cervical cancer.

It should be emphasized that due to the high frequency (up to 25%) of HPV infections in younger women under the age of 30, HPV tests based on DNA analysis have lower specificity and limited use, as a single test does not distinguish between transient and persistent infection, which is associated with the risk of developing dysplasia and cancer. In this age group, HPV DNA tests are helpful in cases of equivocal Pap smear results (ASC-US) and low-grade dysplasia (CIN1 or LSIL), as well as for monitoring treatment, for example, after surgical conization. For prognostic purposes, HPV DNA tests should generally only be used in women over the age of 30.

New-generation tests based on HPV mRNA analysis can be used in women of all ages and have the highest diagnostic and prognostic value – the positive predictive value (PPV) of these tests is at least twice as high as that of viral DNA analysis.

Enter one-time code: Show
Invalid code entered. Please try again.